Your browser doesn't support javascript.
loading
Proteasome-Inhibitor-Based Primary Therapy for Antibody-Mediated Rejection in a Renal Transplant Recipient / 대한내과학회지
Korean Journal of Medicine ; : 780-785, 2011.
Article de Ko | WPRIM | ID: wpr-143821
Bibliothèque responsable: WPRO
ABSTRACT
Donor-specific anti-human leukocyte antigen antibodies (DSA) following kidney transplantation predict the evolution of humoral rejection and reduced graft survival. Rapid, complete elimination of DSA during antibody-mediated rejection (AMR) is rarely achieved with traditional antihumoral therapies. We report the case of a 39-year-old female who was admitted for increasing azotemia and diagnosed with AMR based on diffusely positive histological changes on C4d immunostaining. In this case, bortezomib reversed the histological changes and induced a reduction in DSA. Proteasome-inhibitor-based combination therapy is a potential means for rapid DSA elimination in antibody-mediated rejection in renal transplant recipients.
Sujet(s)
Mots clés
Texte intégral: 1 Indice: WPRIM Sujet Principal: Fragments peptidiques / Pyrazines / 12481 / Acides boroniques / Complément C4b / Transplantation rénale / Transplants / Azotémie / Inhibiteurs du protéasome / Bortézomib Limites du sujet: Adult / Female / Humans langue: Ko Texte intégral: Korean Journal of Medicine Année: 2011 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Fragments peptidiques / Pyrazines / 12481 / Acides boroniques / Complément C4b / Transplantation rénale / Transplants / Azotémie / Inhibiteurs du protéasome / Bortézomib Limites du sujet: Adult / Female / Humans langue: Ko Texte intégral: Korean Journal of Medicine Année: 2011 Type: Article